TipRanks Raymond James: These 3 Stocks Are Poised to Surge by Over 80% We’re a little over one week past the Presidential election, and the market reaction shows that that investors are pleased. While the election margins were razor thin, the will of the voters came through: they rejected Donald Trump, and his brash, in-your-face style, but they also rejected the Democratic Party on policy; the Dems lost seats in the House, will likely not take control of the Senate, and also lost ground at… Source link
Read More »Bill Ackman Bets Against Market Recovery Again, Despite COVID-19 Vaccine Hopes
TipRanks 3 “Strong Buy” Stocks That Tick all the Boxes It’s been said that gridlock is a feature, not a bug, of the US Constitution, and we may be about to find that out. The election results have left some questions to be resolved, but a few things are coming clear: Democrat Joe Biden is the winner of the Presidential race, but down ballot, the Republicans appear to have made important gains. We’re looking at the prospect of divided government – a Biden Administration with a… Source link
Read More »The German company behind the potential first COVID-19 vaccine
Globe Newswire Global Minimally Invasive Surgery Industry Global Minimally Invasive Surgery Market to Reach $90. 4 Billion by 2027. Amid the COVID-19 crisis, the global market for Minimally Invasive Surgery estimated at US$49 Billion in the year 2020, is projected to reach a revised size of US$90.New York, Nov. 10, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Minimally Invasive Surgery Industry” – https://www.reportlinker.com/p05961044/?utm_source=GNW… Source link
Read More »Pfizer vaccine news sends AMC, travel and entertainment stocks on a tear on recovery hopes
AMC (AMC) and other entertainment stocks surged on Monday in the wake of Pfizer (PFE) and BioNTech (BNTX) announcing positive news about their leading COVID-19 vaccine candidate, which demonstrated a high level of efficacy in testing. Even as the U.S. topped 10 million coronavirus cases, markets — which for months have been pricing in hopes of an end to the crisis — skyrocketed on the news. The Dow (^DJI) and S&P 500 (^GSPC) both opened at record highs, tempering those gains slightly by… Source link
Read More »COVID-19 vaccine: BioNTech and Pfizer report 90% effectiveness in trials – Yahoo Finance UK
Business Wire LX Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds LexinFintech Holdings Ltd. Investors of Class Action and Lead Plaintiff Deadline: November 9, 2020 Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against LexinFintech Holdings Ltd. (“LexinFintech” or the “Company”) (NASDAQ: LX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LexinFintech securities (a) pursuant and/or traceable to… Source link
Read More »Stocks Surge to All-Time High on Vaccine Progress: Markets Wrap
(Bloomberg) — Stocks are extending a global rally on the clearest sign of progress yet in developing a vaccine to stem the Covid-19 pandemic. Futures on the S&P 500 jumped 3% after news that the vaccine being developed by Pfizer Inc. and BioNTech SE prevented more than 90% of infections in a study of tens of thousands of volunteers. Contracts on the Russell 2000 Index of small-cap stocks surged 7%. Pfizer’s Covid Vaccine Prevents 90% of Infections in Large Study The vaccine announcement… Source link
Read More »World’s largest coronavirus vaccine trial study begins in U.S. – Yahoo! Voices
[unable to retrieve full-text content]World’s largest coronavirus vaccine trial study begins in U.S. Yahoo! Voices Source link
Read More »Stock futures advance after new Moderna data stokes vaccine optimism
Stock futures opened higher Tuesday evening after newly published data from Moderna (MRNA) fueled hopes that a vaccine providing protection against Covid-19 would be developed in the relative near-term. Moderna’s vaccine produced neutralizing antibodies in all 45 patients included in an early-stage human safety trial, according to data published after market close by the peer-reviewed New England Journal of Medicine. The data built on earlier promising, but incomplete, results Moderna had… Source link
Read More »